Anna Secher
Director - Scientific Novo Nordisk
Anna Secher is a Scientific Director within Global Research at Novo Nordisk. She graduated as a M.Sc. in 2003 and has a PhD in Neuroscience from the University of Copenhagen, Denmark. Anna has been involved in drug discovery and development within endocrinology, obesity and diabetes research since she joined Novo Nordisk more than 16 years ago. For the past decades Anna?s research has centred around the mechanistic understanding of key therapeutics such as GLP-1 and amylin. In addition, she works as a scientific coordinator and project manager within several international research collaborations and early drug discovery programs. Anna’s area of expertise is the brain control of metabolism and metabolic-related disorders, with a focus on supporting the development of new treatment therapies and understanding the mechanism of action of drugs for obesity, diabetes, and cognitive impairment.
Seminars
- Compare emerging efficacy, tolerability, titration and discontinuation patterns across selective amylin agonists, balanced agonists and amylin-containing combinations, distinguishing molecule-specific effects from potential class effects
- Interrogate whether current clinical performance supports proposed hypotheses around receptor selectivity, exposure, signalling bias and dose escalation, identifying which mechanistic assumptions require revision
- Translate clinical successes and disappointments back into preclinical decisionmaking, enabling earlier programs to update target product profiles, assays and candidate-selection criteria before entering costly trials
